Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

6.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.3K
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

7.6K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.6K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

989
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
989

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).

Advances in therapy·2018
Same author

The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?

Primary care diabetes·2018
Same author

Thoughts, Words, Action: The Alma-Ata Declaration to Diabetes Care Transformation.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2018
Same author

Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology.

European endocrinology·2018
Same author

Lessons From LEADER - All-round Leadership.

European endocrinology·2018
Same author

Beta-cell Insufficiency.

European endocrinology·2018
Same journal

Socioeconomic inequalities and trends in the prevalence of childhood obesity phenotypes in Iran from 2000 to 2030.

Journal of diabetes and metabolic disorders·2026
Same journal

Hybrid deep learning models for diabetic retinopathy stage classification using fundus images.

Journal of diabetes and metabolic disorders·2026
Same journal

Heart rate nondipping pattern and left atrial remodeling as a marker of cardiac target organ damage in patients with type 2 diabetes.

Journal of diabetes and metabolic disorders·2026
Same journal

Association between serum vitamin D levels and peri-implant diseases.

Journal of diabetes and metabolic disorders·2026
Same journal

Self-management in Korean immigrants with type 2 diabetes in the United States: a systematic review.

Journal of diabetes and metabolic disorders·2026
Same journal

Smoking status and determinants among Iranian adults with diabetes: findings from the national STEPS 2021 survey.

Journal of diabetes and metabolic disorders·2026
See all related articles

Related Experiment Video

Updated: Apr 14, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.3K

Insulin initiation: bringing objectivity to choice.

Sanjay Kalra1, Yashdeep Gupta2

  • 1Bharti Hospital, Kunjpura Road, Karnal, 132001 Haryana India.

Journal of Diabetes and Metabolic Disorders
|April 16, 2015
PubMed
Summary
This summary is machine-generated.

Choosing initial insulin therapy lacks objective guidelines. This paper proposes objective parameters to help clinicians select the most appropriate insulin regimen for individuals with diabetes.

Keywords:
Basal insulinBasal-bolus insulinDiabetesInsulinIntensive insulinPrandial insulinPremixed insulin

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K

Related Experiment Videos

Last Updated: Apr 14, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.3K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Current insulin initiation relies on subjective factors like diabetes severity and physician experience.
  • Lack of objective criteria hinders optimal insulin regimen selection for patients.
  • Limited large-scale studies provide guidance on personalized insulin therapy.

Purpose of the Study:

  • To propose objective parameters for guiding the initial choice of insulin therapy.
  • To address the need for evidence-based criteria in insulin selection.
  • To improve the accuracy and appropriateness of starting insulin treatment.

Main Methods:

  • Review of current practices in insulin initiation.
  • Identification and proposal of objective clinical and patient-related parameters.
  • Discussion of the potential impact of objective criteria on treatment outcomes.

Main Results:

  • Subjective criteria currently dominate insulin choice.
  • No universally accepted objective guidelines exist for initiating insulin.
  • Proposed objective parameters include factors beyond current subjective assessments.

Conclusions:

  • Objective parameters are needed to personalize insulin therapy selection.
  • Implementing objective criteria can lead to more accurate and effective initial insulin choices.
  • Further research and expert consensus are required to validate these proposed parameters.